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SUMMARY 
Trimetrexate is a potent inhibitor of dihydrofolate reductase and has demonstrated sig- 
nificant antitumor activity against murine and human cell lines both in vitro and against 
several murine transplanted tumors. The importance of antifolate concentration and 
exposure time in determining toxic and therapeutic effects necessitates an assay of suitable 
sensitivity, accuracy and specifity for investigation of trimetrexate pharmacokinetics. This 
paper describes a gas chromatographic-mass spectrometric (GC-MS) procedure using 
selected-ion monitoring (SIM) for the determination of plasma trimetrexate levels. Using 
the C,, Bond-Elut extraction columns, the drug and internal standard are removed from 
plasma, derivatized to their bis(trimethylsily1) derivatives and analysed by GC-SIM-MS. 
The reproducibility of the daily standard curves had coefficients of variation ranging from 
4.9 to 11.4%. The precision of the assay yielded a coefficient of variation ranging from 5.6 
to lO.l%, and the concentration means for the seeded control samples were found to be 
within -3.7 to +0.7% of the theoretical values for trimetrexate. No interfering peaks have 
been observed in application of the procedure on patient samples. The minimum detectable 
level under the conditions described was 0.005-0.014 PM trimetrexate. 
INTRODUCTION 
Trimetrexate, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyan~ino)methyl] - 
quinazoline (TMQ), was originally synthesized by Elslager and Davoll [l] . It is 
a potent inhibitor of dihydrofolate reductase (DHFR) (5,6,7,Stetrahydro- 
folate:NADP+ oxidoreductase, EC 1.5.1.3) [2] and has demonstrated 
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significant antitumor activity against murine and human cell lines both in vitro 
and against several murine transplanted tumors [ 3, 41. TMQ is more lipophilic 
than the classical antifolate, methotrexate, and has demonstrated an increased 
uptake into neoplastic cells compared to methotrexate [5]. Also, TMQ’s 
enhanced lipophilicity may afford it greater penetration into the central 
nervous system (CNS) and, therefore, greater efficacy than methotrexate 
against CNS neoplasms. Since TMQ does not utilize the reduced folate 
transport system in its entry into cells (as does methotrexate), it has been 
shown effective in vitro against a human lymphocytic leukemia cell line 
resistant to methotrexate by virtue of impaired drug transport [6]. 
The importance of antifolate concentration and exposure time in 
determining toxic and therapeutic effects both in vitro and in vivo in 
experimental animal tumors has been established [7-lo]. These investigators 
have shown that a cell-type dependent minimal concentration was needed 
to inhibit cell growth or DNA synthesis and that no additional benefit of 
cell kill (in leukemia L1210 cells) was obtained with higher antifolate (metho- 
trexate) concentrations [9]. Studies in experimental animal systems have also 
shown that biological response to antifolates is determined by exposure time 
and is selective for individual tissues [ 11-131. These findings suggest a 
therapeutic rationale for the prolonged infusion of TMQ at rigidly controlled 
dose rates which achieve steady-state TMQ plasma levels toxic to neoplastic 
cells but below the toxic threshold of bone marrow cells from that individual 
patient. 
Such exacting therapy will require a complete understanding of the 
pharmacokinetics and pharmacodynamics of TMQ. This, in turn, necessitates 
the availability of accurate, sensitive and specific assay procedures for the drug 
in biological fluids. Previous methods for TMQ determination were based on 
either high-performance liquid chromatographic (HPLC) [14, 151 or DHFR 
inhibition [ 14,161 techniques. Problems with sample TMQ recovery [ 141 were 
alleviated with the use of the Cl8 Bond-Elut system and resulted in a sensitive 
(0.05 PM detection limit) and specific TMQ HPLC assay [15] . However, no 
internal or external standards were employed. The DHFR inhibition 
procedures are highly sensitive (0.005 pM TMQ detectability), but suffer from 
a lack of specificity, a 15-20% variability and an extremely narrow range of 
linearity in the concentration-inhibition curve [ 161 . Most recently, a competi- 
tive protein binding assay for TMQ has been reported [ 171. This method, 
although sensitive in the range of 0.002 PM TMQ, has not yet been fully charac- 
terized as to its TMQ specificity. 
This paper describes a sensitive, specific and internally standardized assay 
procedure for the determination of plasma TMQ levels. The sample preparation 
utilizes the Cl8 Bond-Elut system [ 151, modified for optimal compatibility 
with subsequent chemical derivatization and gas chromatographic-mass 
spectrometric (GC-MS) procedure using selected-ion monitoring (SIM). 
EXPERIMENTAL 
Reagents 
Trimetrexate and 2,4-diamino-5-methyl-6-[ (4-chloroanilino)methyl] - 
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quinazoline were obtained from Warner Lambert/Parke Davis (Ann Arbor, MI, 
U.S.A.). Methanol was purchased from Burdick and Jackson Labs. (Muskegon, 
MI, U.S.A.). Triethylamine (99% purity) was purchased from Aldrich 
(Milwaukee, WI, U.S.A.). N-Methyl-N-trimethylsilyltrifluoroacetamide 
(MSTFA) was purchased from Pierce (Rockford, IL, U.S.A.). The Cn, Bond- 
Elut sample preparation columns, with a 500-mg capacity column bed, were 
purchased from Analytichem (Harbor City, CA, U.S.A.). A vacuum manifold 
with the capacity of holding ten sample preparation columns for simultaneous 
sample extractions was also purchased from Analytichem. 
Stock solutions 
A TMQ solution (2.7 1 mM in methanol) and a 2,4-diamino&methyl-6-[(4- 
chloroanilino)methyl] quinazoline (internal standard, I.S.) solution (1.05 mM 
in methanol) were prepared and stored at -30” C. 
Standards 
The TMQ stock solution was diluted 1:lOO with water to yield the TMQ 
standard solution No. 1 containing 0.027 m&f TMQ. TMQ standard solution 
No. 2 containing 0.27 mM TMQ was prepared by diluting the TMQ stock 
solution 1:lO with water. The I.S. stock solution was diluted with water to 
yield the IS. solution containing 0.105 mM I.S. Standard TMQ and I.S. 
solutions were prepared from stock solutions immediately before use. 
Quality-control (QC) samples at two concentrations (0.27 and 1.35 PM 
TMQ) were prepared by spiking blank plasma with the appropriate volumes of 
the TMQ standards. After mixing, 1.2-ml aliquots were transferred to poly- 
propylene tubes, tightly capped, and stored frozen at -3O’C. Three QC 
samples of each concentration were included with every group of experimental 
samples to be analyzed. 
GC-SIM-MS parameters 
The instrument used in these studies was a Hewlett-Packard Model 5987A 
gas chromatograph-mass spectrometer with electron-impact (EI) ionization 
and selected-ion monitoring. Temperature zones were set as follows: ion source 
temperature, 250” C; analyzer temperature, 300” C; transfer line temperature, 
300°C. The electron energy was set at 70 eV and the multiplier voltage was 
2400 V. The mass ion at m/z 331 was monitored from 1.0 to 4.2 min into the 
run. 
Separation of the trimethylsilyl (TMS) derivatives of TMQ and I.S. was 
accomplished using a fused-silica capillary column (5 m X 0.32 mm I.D.) 
coated with a cross-linked methyl silicone liquid phase (0.17-mm film 
thickness). Gas chromatographic conditions were: injection port and GC-MS 
interface oven temperatures were 300°C; GC column oven temperature was 
programmed from 200” C (0.1 min hold) at 15”C/min to 300°C; carrier gas 
(helium) flow-rate was set to 1.0 ml/min. 




To 1.0 ml plasma were added 1.05 run01 I.S. (10 ,ul of the IS. standard 
solution). The sample was vortexed and loaded onto a Cl8 Bond-Elut column 
which was prewet by aspirating two column reservoir volumes of methanol 
followed by two column reservoir volumes of water through the column. Only 
the excess water was pulled through the column before adding the sample. 
The columns were then washed with 6.0 ml.distilled water followed by 3.0 ml 
methanol. To this point all eluates were discarded. Drug and I.S. were eluted 
from the column in 1.0 ml methanol-10% (v/v) triethylamine (TEA). The 
methanol-TEA eluates were dried in a vacuum centrifuge heated to 45°C. 
Trimethylsilylation of TMQ and I.S. was accomplished using MSTFA. 
MSTFA (50 ~1) was added to the dried residue, the tubes were vortexed and 
incubated at room temperature for 15 min. A volume (0.5-2.0 ~1) of the 
resulting derivatization solution was injected for GC-SIM-MS analysis. 
Standard calibration curve 
Blank plasma samples were spiked in duplicate with the appropriate volumes 
of the TMQ standard solutions Nos. 1 and 2 to concentrations ranging from 
0.14 to 2.71 ,uM TMQ and subjected to the sample preparation procedure 
described above. Calibration curves were run (in duplicate) with each set of 
experimental samples. 
Calculations 
Calibration curves were constructed by plotting the ratio of the integrated 
peak area of TMQ to that of the internal standard as a function of the plasma 
TMQ concentration. The best-fit straight line was determined using a simple 
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Fig. 1. Molecular structures and EI mass spectra of bis(TMS) derivatives of TMQ (A) and 
I.S. (B). 
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linear regression of the ln(peak-height ratio) versus In(concentration) data. 
The TMQ concentrations of unknown samples were calculated using the 
results of the regression analysis. 
RESULTS AND DISCUSSION 
The molecular structures and EI mass spectra of the TMS derivatives of TMQ 
and I.S. are shown in Fig. 1. Also indicated is the EI fragmentation pattern 
resulting in the identical mass ion of maximum abundance (m/z 331) for both 
the TMQ and I.S. bis(TMS) derivatives. Since this mass ion is so overwhelming- 
ly abundant in the mass spectra of TMQ and the I.S., little could be gained by 
monitoring any additional mass ions. 
Figs. 2, 3 and 4 illustrate typical total-ion chromatograms from the 
GC-SIM-MS analyses of control (blank) human plasma with added internal 
standard (Fig. 2), a TMQ-spiked calibration sample containing 0.14 I1M TM& 
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Fig. 2. Typical chromatogram of control (blank) human plasma with added internal 
standard, Insert shows the TMQ region of the chromatogram on an expanded scale. 
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Fig. 3. Typical chromatogram of TMQ-spiked control human plasma at a concentration of 
0.14 PM TMQ. Insert shows the TMQ region of the chromatogram on an expanded scale. 
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Fig. 4. Typical chromatogram of patient plasma containing 0.23 PM TMQ. Insert shows the 
TMQ region of the chromatogram on an expanded scale. 
inserts depict with a greatly expanded scale the region of the chromatogram 
containing the TMQ peak. If the minimum detectable level is defined as three 
times the background signal noise, then from the insert of Fig. 2 one can 
estimate that under these conditions the minimum detectable level would be 
0.005--0.014 PJM TMQ. Throughout our clinical studies, no interfering peaks 
were present in the several hundred patient plasma samples assayed. The chro- 
matographic analysis time for each sample was 4.2 min, and this laboratory has 
routinely processed 50-~100 samples in the normal S-h working day. 
The validity of the assay procedure was established through a careful study 
of the linearity of response, reproducibility, accuracy and precision. The peak- 
TABLE I 
BACK-CALCULATED CONCENTRATIONS FOR TMQ STANDARDS 
Data were obtained through linear regression analysis of In(peak-area ratio) versus ln(concen- 
tration) of added TMQ. 
Day Concentration (cl&f) 
0.14 0.27 1.35 2.71 
Slope Intercept r 
1 0.14 0.28 1.14 2.71 0.97 -0.28 0.997 
0.13 - 1.39 3.02 
0.17 0.24 1.32 2.79 
2 0.13 0.26 1.39 2.85 0.98 -0.37 0.999 
0.14 0.29 1.27 2.67 
0.15 0.27 1.32 2.70 
3 0.17 0.27 1.38 2.91 1.01 -0.29 0.998 
0.14 0.25 1.33 2.76 
0.13 0.27 1.32 2.57 
Lean 0.14 9 0.27 8 9 1.32 9 2.78 0.99 3 -0.31 3 3 0.998 
S.D. 0.016 0.016 0.078 0.136 0.02 0.05 0.001 
C.V. (%) 11.4 5.9 5.9 4.9 2.0 16.1 0.1 
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TABLE II 
TRIMETREXATE CONCENTRATIONS IN SEEDED CONTROL SAMPLES ASSAYED 
OVER A THREE-DAY PERIOD 
Day Trimetrexate concentration (~44) 
0.27 /.iM 1.35 pM 
1 0.27 1.30 
0.23 1.34 
0.23 1.39 
2 0.28 1.44 
0.26 1.45 
0.28 1.28 
3 0.26 1.28 
0.31 1.45 
0.24 1.28 
Mean (PM) 0.26 1.36 
Standard deviation (uM) 0.03 0.08 
Coefficient of variation (%) 10.1 5.6 
Deviation from theoretical (%) -3.7 +0.7 
area ratio was directly proportional to the TMQ concentrations over the tested 
range of 0.07-2.71 PM. The best-fit lines were obtained using linear regression 
analysis of the In-transform data. To test the reproducibility of this procedure, 
calibration samples were prepared in triplicate on three successive days. The 
results of these studies are summarized in Table I. Triplicate QC samples 
at each concentration (0.27 and 1.35 MM TMQ) were run in parallel. The 
reproducibility of the daily standard curves had coefficients of variation which 
ranged between 11.4% (at lowest concentration) to 4.9% (at highest concentra- 
tion) . 
The accuracy and precision of the method were assessed by seeding plasma 
at TMQ concentrations of 0.27 and 1.35 PM. Triplicate QC samples at each 
concentration were assayed on each of three consecutive days. Table II 
summarizes these results. The assay precision was found to have coefficients 
of variation ranging from 5.6 to 10.1%. The concentration means for the 
seeded control samples were found to be within -3.7 to +0.7% of the 
theoretical values for TMQ. 
Application of the method developed was demonstrated by measuring the 
steady-state plasma TMQ levels in a patient receiving each of two intravenous 
TMQ infusions (14.5 Mmol TMQ per 40 h and 21.7 pmol TMQ per 40 h). 
Peripheral venous blood was sampled at 0, 16, 24 and 40 h into the infusion. 
The steady-state venous plasma TMQ levels (mean ? SD.) attained during 
the two infusion rates were 0.16 + 0.02 and 0.23 + 0.03 PM TMQ. 
The GC-SIM-MS assay described here for plasma TMQ levels is sufficiently 
sensitive and accurate to be used in pharmacokinetic studies and therapeutic 
monitoring of this new non-classical antifolate. To date, the analysis of several 
hundred patient plasma samples, as well as blank plasma samples spiked with 
1.0 pg/ml folic acid, methotrexate, 3’,5’-dichloroamethopterin or aminopterin, 
has failed to elicit any chromatographic interferences, Studies are presently 
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underway to investigate necessary modifications to the procedure for 
applicability in the study of TMQ metabolism and its application to the deter- 
mination of TMQ levels in tissues and biological fluids other than plasma. 
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